Statistically significant but clinically unimportant: a systematic review and meta-analysis of the analgesic benefits of erector spinae plane block following breast cancer surgery

Nasir Hussain, Richard Brull, Jordan Noble, Tristan Weaver, Michael Essandoh, Colin JL McCartney, Faraj W Abdallah

ABSTRACT

The novel erector spinae plane block (ESPB) has been reported to provide important postoperative analgesic benefits following a variety of truncal and abdominal surgical procedures. However, evidence of its analgesic efficacy following breast cancer surgery, compared with parenteral analgesia, is unclear. This meta-analysis evaluates the analgesic benefits of adding ESPB to parenteral analgesia following breast cancer surgery. Databases were searched for breast tumor resection trials comparing ESPB to parenteral analgesia. The two co-primary outcomes examined were 24-hour postoperative oral morphine equivalent consumption and area-under-curve of rest pain scores. We considered reductions equivalent to 3.3 cm.h and 30 mg oral morphine in the first 24 hours postoperatively for the two co-primary outcomes, respectively, to be clinically important. We also assessed opioid-related side effects and long-term outcomes, including health-related quality of life, persistent postsurgical pain and opioid dependence. Results were pooled using random effects modeling. Twelve trials (699 patients) were analyzed. Moderate quality evidence suggested that ESPB decreased 24-hour morphine consumption and area-under-curve of rest pain by a mean difference (95% CI) of −17.60 mg (−24.27 to −10.93) and -2.74 cm.h (−3.09 to −2.39), respectively; but these differences were not clinically important. High-quality evidence suggested that ESPB decreased opioid-related side effects compared with parenteral analgesia by an OR (95% CI) of 0.43 (0.28 to 0.66). None of the studies evaluated long-term block benefits. Adding ESPB to parenteral analgesia provides statistically significant but clinically unimportant short-term benefits following breast cancer surgery. Current evidence does not support routine use of ESPB. Given the very modest short-term benefits and risk of complications, the block should be considered on a case-by-case basis.

BACKGROUND

Characterized by its technical simplicity and wide dermatomal spread (T1 to L3),1,2 the novel ultrasound-guided erector spinae myofascial plane block (ESPB) has gained popularity among practitioners for its benefits across a variety of truncal and abdominal surgical procedures.3 Applied to breast cancer surgery, the ESPB is purported to enhance pain control.4 However, much of the reviews evaluating ESPB in breast surgery are qualitative in nature3 and limited by pooling breast surgery together with thoracic procedures;5 while the most recent investigation conducted multiple comparisons to other truncal blocks and provided statistical conclusions devoid of clinical interpretations.6 As for individual randomized clinical trials, the results have been decidedly mixed and difficult to interpret, primarily because they involved comparisons to various other blocks.8,11,12

In order to definitively address the analgesic efficacy of ESPB for breast cancer surgery, we aimed to compare the analgesic effects of ESPB to parenteral analgesia alone. The most valid, accurate and least biased evaluation of the treatment effect of an intervention is derived from comparisons with a placebo or no intervention.13

This systematic review and meta-analysis aims to identify the potential clinical role of ESPB in the setting of breast cancer surgery. We aimed to quantify the benefits of adding ESPB to parenteral analgesia compared with parenteral analgesia alone. Postoperative pain severity and analgesic consumption during the first 24 hours were designated as co-primary outcomes. We also assessed the effects of ESPB on patient satisfaction, health-related quality of life, risk of persistent postsurgical pain and long-term opioid dependence.

METHODS

In preparing this manuscript, we adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).14 We sought randomized controlled trials (RCTs) that analyzed the analgesic effects of ESPB compared with parenteral analgesia in patients undergoing breast cancer surgery. These studies were evaluated using a predesigned protocol that was registered with the international prospective register of systematic reviews (PROSPERO) under the number CRD42020170496.

Eligibility criteria

We searched electronic databases for unilateral breast cancer surgery trials where adult patients were randomized to ESPB as an intervention compared with parenteral analgesia. Studies that had a co-intervention other than ESPB (eg, another...
Table 1: Study characteristics and outcomes of interest assessed in included studies

| Author/year | Surgery | N  | Groups (n) | Surgical anesthetic | Primary outcome | Rest pain scores | Dynamic pain scores | Opioid consumption | Time to first analgesic request | Assessment of block success | Opioid-related adverse effects | Block-related complications | Patient satisfaction | PACU discharge time | Hospital discharge time | Quality of life outcomes | Functional outcomes | Persistent postsurgical pain |
|-------------|---------|----|------------|--------------------|-----------------|------------------|-------------------|-------------------|---------------------------|---------------------------|-----------------------------|--------------------------|-------------------|-----------------|-------------------|---------------------|-------------------|
| Gürkan 2018 | MRM, lumpectomy; SLNB, ALND | 50  | 1.ESPB (25) 2. Control (25) | General | Opioid consumption | ● | ● | ● |
| Aksu 2019  | MRM, lumpectomy; SLNB, ALND | 50  | 1.ESPB (25) 2. Control (25) | General | Opioid consumption | ● | ● | ● |
| Arora 2019  | MRM/LNND | 60  | 1.ESPB (30) 2. Control (30) | General | Opioid consumption | ● | ● | ● |
| Singh 2019  | MRM | 40  | 1.ESPB (20) 2. Control (20) | General | Opioid consumption | ● | ● | ● |
| Wang 2019   | MRM | 150 | 1.ESPB (60) 2. PVB (60) 3. Control (30) | General | N/S | ● | ● | ● |
| Dikusi 2020 | MRM/LNND | 62  | 1.ESPB (33) 2. Control (33) | General | Time to analgesic request | ● | ● | ● |
| He 2020     | MRM/LNND | 40  | 1.ESPB (20) 2. Control (20) | General | Pain scores | ● | ● | ● |
| Gupta 2019  | Breast cancer surgery | 15  | 1.ESPN (10) 2. Control (5) | General | N/S | ● | ● | ● |
| Marwani 2020 | MRM, lumpectomy; ALND | 50  | 1.ESPB (25) 2. Control (25) | General | Opioid consumption | ● | ● | ● |
| Sedarni 2020 | MRM | 100 | 1.ESP (50) 2. Control (50) | General | Opioid consumption | ● | ● | ● |
| You 2021    | MRM | 82  | 1. ESPB (41) 2. Control (41) | General | Quality of recovery | ● | ● | ● |

*Data provided either on clinical trial registry. ALND, axillary lymph node dissection; Early, ≤24 hours; ESPB, erector spinae plane block; Late, >24 hours; MRM, modified radical mastectomy; PACU, post-anesthesia care unit; PVB, paravertebral blockade; SAPB, serratus anterior plane block; SLNB, sentinel lymph node biopsy.
block), which precluded identifying the analgesic effects of ESPB alone, were not considered. Studies of catheter-based continuous blocks were not considered. All types of breast tumor resection with or without concomitant axillary interventions were eligible, including mastectomy or partial mastectomy with or without axillary lymph node dissection or sentinel lymph node biopsy.

Table 2  Local anesthetic techniques for ESPB and analgesic regiments of included studies

<table>
<thead>
<tr>
<th>Author/year</th>
<th>Pre-incisional analgesia</th>
<th>Surgical analgesia</th>
<th>Supplemental postoperative analgesia</th>
<th>Block technique</th>
<th>Level of block</th>
<th>Localization</th>
<th>Assessment of block success</th>
<th>ESPB bolus</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gürgan 2018</td>
<td>None</td>
<td>Fentanyl 2 mcg/kg IV</td>
<td>Paracetamol 1 g IV; tramadol 100 mg IV; PCA morphine</td>
<td>Preop, 1, 4</td>
<td>T4</td>
<td>USG</td>
<td>No</td>
<td>20 mL 0.25% bupivacaine</td>
</tr>
<tr>
<td>Aksu 2019</td>
<td>None</td>
<td>Fentanyl 2 mcg/kg IV</td>
<td>Paracetamol 1 g IV; tramadol 100 mg IV; PCA morphine</td>
<td>Preop, 1, 4</td>
<td>T2 and T4</td>
<td>USG</td>
<td>No</td>
<td>20 mL 0.25% bupivacaine</td>
</tr>
<tr>
<td>Arot 2019</td>
<td>NS</td>
<td>Fentanyl 0.5 mcg/kg-1 mcg/kg IV</td>
<td>PCA morphine</td>
<td>Preop, 1, 4</td>
<td>T5</td>
<td>USG</td>
<td>Yes</td>
<td>0.4 mcg/kg 0.5% ropivacaine</td>
</tr>
<tr>
<td>Singh 2019</td>
<td>None</td>
<td>Morphone 0.1 mcg/kg IV</td>
<td>Diclofenac 1.5 mg/kg IV; morphine 3 mg IV pm</td>
<td>Preop, 1, 4</td>
<td>T5</td>
<td>USG</td>
<td>Yes</td>
<td>20 mL 0.5% bupivacaine</td>
</tr>
<tr>
<td>Wang 2019</td>
<td>1 mcg/kg Dexmed</td>
<td>Sufentanil 0.4 mcg/kg IV; remifentanil 3.5 mg/ml to 4.5 mg/ml IV</td>
<td>Flurbiprofen 50 mg PO pm; sufentanil 5 mcg IV pm; PCA sufentanil</td>
<td>Preop, 1, 4</td>
<td>T4 and T5</td>
<td>USG</td>
<td>N/S</td>
<td>20 mL 0.375% ropivacaine</td>
</tr>
<tr>
<td>Divatia 2019</td>
<td>NS</td>
<td>Fentanyl 0.5 mg/kg IV</td>
<td>Paracetamol 15 mg/kg IV; fentanyl 1 IV pm</td>
<td>Intraop, 1, 4</td>
<td>T5</td>
<td>USG</td>
<td>Yes</td>
<td>20 mL 0.25% bupivacaine</td>
</tr>
<tr>
<td>Gupta 2020</td>
<td>0.5 mcg/kg/hr Dexmed</td>
<td>Fentanyl 2 mcg/kg (if no block); ketamine 10 mg bolus (if block)</td>
<td>PCA morphine</td>
<td>Preop, 1, 4</td>
<td>T5</td>
<td>USG</td>
<td>N/S</td>
<td>30 mL 0.5% ropivacaine</td>
</tr>
<tr>
<td>Gürgan 2020</td>
<td>None</td>
<td>Fentanyl 2 mcg/kg IV; tramadol 100 mg IV; paracetamol 1 g IV</td>
<td>Paracetamol 1 g IV qgh; PCA morphine</td>
<td>Preop, 1, 4</td>
<td>T4</td>
<td>USG</td>
<td>No</td>
<td>20 mL 0.25% bupivacaine</td>
</tr>
<tr>
<td>He 2020</td>
<td>NS</td>
<td>NS</td>
<td>Flurbiprofen 50 mg IV pm</td>
<td>Preop, 1, 4</td>
<td>T3</td>
<td>USG</td>
<td>N/S</td>
<td>20 mL 0.5% ropivacaine</td>
</tr>
<tr>
<td>Marzouk 2020</td>
<td>NS</td>
<td>NS</td>
<td>PCA morphine</td>
<td>Preop, 1, 4</td>
<td>T4 or T5</td>
<td>USG</td>
<td>N/S</td>
<td>40 mL 0.375% ropivacaine</td>
</tr>
<tr>
<td>Seelam 2020</td>
<td>None</td>
<td>Fentanyl 0.5 mcg/kg to 1 mcg/kg IV; paracetamol 1 g IV</td>
<td>Paracetamol 1 g IV qgh; morphine 2 mg to 3 mg IV pm</td>
<td>Preop, 1, 4</td>
<td>T4</td>
<td>USG</td>
<td>No</td>
<td>30 mL 0.25% bupivacaine</td>
</tr>
<tr>
<td>Yao 2020</td>
<td>Flurbiprofen 50 mg IV</td>
<td>Sufentanil 0.5 mcg/kg IV; flurbiprofen 50 mg IV</td>
<td>Flurbiprofen 50 mg qgh; sufentanil 2 mcg IV pm PCA sufentanil</td>
<td>Preop, 1, 4</td>
<td>T4</td>
<td>USG</td>
<td>No</td>
<td>25 mL 0.25% ropivacaine</td>
</tr>
</tbody>
</table>

*Study from clinical trials registry. Dexmed, dexmedetomidine; ESPB, erector spinae plane block; h, hour; Intraop, intraoperative; IV, intravenous; LA, local anesthesia; mcg, microgram; min, minute; mL, milliliter; mg, milligram; N/S, not specified; PCA, patient-controlled analgesia; Preop, preoperative; pm, as needed; q, every; USG, ultrasound guidance.

**Figure 1** Forest plot of cumulative oral morphine equivalent consumption at 24 hours for erector spinae plane block (ESPB) versus parenteral analgesia (Control). Pooled estimates of the weighted mean difference are shown with 95% CIs. Pooled estimates are represented as diamonds and lines represent the 95% CIs. IV, intravenous.
Cosmetic procedures (eg, augmentation, reduction mammoplasty or isolated breast reconstruction) or use of tumescence were exclusion criteria. Also, trials of volunteers or those not reporting analgesic outcomes were excluded. No language restrictions were placed; and non-English studies were translated using an online translator.

Search methods
A systematic search strategy was created by an evidence-based medicine librarian (LB) for the US National Library of Medicine database, MEDLINE; the MEDLINE In-process and Other Non-Indexed citations database; the Excerpta Medica database, Embase; and the Cochrane Database of Systematic Reviews from October 2016 (date of original ESPB description) to May 1, 2020. The strategy contained key words relating to the following: breast surgery, erector spinae plane, pain control, and analgesia. The complete search strategy for the MEDLINE database can be viewed in online supplemental appendix A. The reference lists for all articles satisfying inclusion criteria were reviewed to identify any potentially relevant trials. We also reviewed clinical trial registries (www.clinicaltrials.gov) (US Clinical Trials Registry), https://apps.who.int (International Clinical Trials Registry Platform; www.ctrri.in (Indian Clinical Trials Registry); https://www.irct.ir (Iranian Clinical Trials Registry); http://www.chictr.org.cn (Chinese Clinical Trials Registry); and http://www.clinicaltrials.in.th (Thai Clinical Trials Registry)) for potentially eligible ongoing or completed trials. Finally, we reviewed the proceedings of international conferences (American Society of Anesthesiologists (ASA) 2011 to 2020, American Society of Regional Anesthesia and Pain Medicine (ASRA) 2013 to 2020, the European Society of Regional Anesthesia (ESRA) 2014 to 2019, American Association of Cancer Research (AACR) 2014 to 2020, and the European Society of Anesthesiology (ESA) 2015 to 2020) for potentially eligible abstracts.

Selection of included studies
Two independent reviewers (NH and JN) screened the search results based on title and abstract alone first; then potentially eligible citations had their full-text versions reviewed. Disagreements were resolved by discussion; if consensus could not be reached, a third reviewer (FA) made the final decision.

Data extraction
Two independent reviewers (NH and TW) carried out data extraction in duplicate. Disagreements were resolved by discussion; if consensus could not be reached, a third reviewer (FA) made the final decision. Extracted data included: year of publication; number of patients; type of surgery performed; intervention and comparator groups; ESPB technique; assessment of block success; means and measures of variance for interval postoperative pain scores and interval postoperative analgesic consumption; additional analgesic outcomes (time to analgesic request, level of patient satisfaction with pain relief; post-anesthesia care unit and hospital discharge times (hours); long-term outcomes (health-related quality of life, persistent postsurgical pain and opioid dependence); safety outcomes (block-related complications as local anesthetic systematic toxicity, bleeding and/or hematoma formation, pneumothorax, or nerve injury); and opioid-related side effects as respiratory depression, excessive sedation, pruritus, constipation, urinary retention). Graphically reported data not reported in textual form were extracted using a graph digitizing software (GraphClick, Arizona Software, USA).

Assessment of methodological quality of individual trials
Using the Cochrane Collaboration tool, the methodological quality of each of the included trials was assessed for risk of bias in six predefined domains including: random sequence generation, allocation concealment, level of blinding of study participants and personnel, blinding of outcome assessment, incomplete outcome data, and selective outcome reporting. For all risks of bias pertaining to patient and assessor blinding, we a priori decided to assign a high risk of detection bias to studies that lacked a sham ESPB. Two independent reviewers (NH and FA) rated each included study as having either a low, unclear, or high risk of bias for each domain.

Methodological quality across trials
The overall methodological quality across statistically pooled outcomes was assessed using the Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) guidelines. GRADE uses five categories—risk of bias, imprecision, inconsistency, indirectness and publication bias to address key issues that influence the quality of evidence which for each outcome is then classified as high, moderate, low, or very low.
Primary and secondary outcomes

The two co-primary outcomes of this meta-analysis were the postoperative 24 hours (1) cumulative postoperative oral morphine equivalent consumption (mg) and (2) difference in the area under the curve (AUC) of the weighted pooled rest pain severity scores. For the AUC analysis, the weighted pooled rest pain scores at 1 hour (post-anesthesia care unit, PACU), 6 hours, 12 hours, and 24 hours postoperatively were used at time points that permit the analgesic effectiveness and capture ESPB onset and offset.

Secondary outcomes included cumulative postoperative oral morphine consumption (mg) during PACU stay as well as the 24-hour to 48-hour time interval; time-to-first analgesic request (hours); time to hospital discharge (hours); postoperative pain severity scores (visual analog scale, VAS) at individual time points (1 hour, 6 hours, 12 hours, 24 hours, 36 hours, and 48 hours postoperatively); patient satisfaction (VAS); postoperative opioid related side effects (postoperative nausea and vomiting, excessive sedation, respiratory depression, pruritus, urinary retention, or constipation); block-related complications (pneumothorax, nerve injury, or local anesthetic systemic toxicity); and long-term (incidence of persistent postoperative pain, health-related quality of life, opioid dependence, and pain-related disability).

Measurement of outcome data

For the purposes of this review, all postoperative pain scores were converted to equivalent 0 to 10 cm VAS scores. All postoperative opioid analgesics administered were converted to oral morphine equivalents (mg) and all measures of patient satisfaction were converted to a VAS score (0=least satisfied and 10=most satisfied). Time-to-event data were presented in hours.

Statistical analyses

We extracted the mean and SD for continuous outcomes; in situations where other measures of centrality and dispersion were reported, previously described statistical conversions were used to estimate these values. For dichotomous outcomes, data were converted to overall incidence numbers. In cases where distinct pain scores were presented were for the breast and axilla, a weighted mean for pain in these two areas was calculated. Data available from one study were presented qualitatively.

Meta-analysis

To account for potential heterogeneity among the pooled studies, continuous data were pooled using the inverse variance method with random-effects modeling, and dichotomous data was pooled using the Mantel-Haenszel with random-effects modeling. For the co-primary outcomes, AUC of pain score and 24-hour analgesic consumption, a weighted mean difference (WMD) with 95% CI and a mean difference with 95% CI were calculated, respectively. Similarly, for secondary outcomes, we calculated a WMD with 95% CI for primary outcomes, AUC of pain score and 24-hour analgesic consumption, and an OR with 95% CI was calculated for dichotomous outcomes. A p value <0.025 was designated as the threshold of statistical significance for the two co-primary outcomes. For the secondary outcomes, we adjusted the threshold for statistical significance in each of the four comparison performed using the Bonferroni-Holm correction.

Table 3: Secondary endpoint results

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Studies included</th>
<th>ESPB, mean (SD) or n/N</th>
<th>Control, mean (SD) or n/N</th>
<th>Mean difference or OR (95% CI)</th>
<th>P value for statistical significance</th>
<th>P value for heterogeneity</th>
<th>I² Test for heterogeneity</th>
<th>Quality of evidence (GRADE)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rest pain at 1 hour (PACU) (cm)</td>
<td>11</td>
<td>1.72 (1.61)</td>
<td>2.78 (1.75)</td>
<td>−1.17 (-1.68 to -0.66)</td>
<td>&lt;0.000001</td>
<td>&lt;0.00001</td>
<td>83%</td>
<td>⊕⊕⊕⊕</td>
</tr>
<tr>
<td>Rest pain at 6 hours (cm)</td>
<td>11</td>
<td>1.67 (1.47)</td>
<td>2.76 (2.11)</td>
<td>−1.17 (-1.67 to -0.66)</td>
<td>0.00001</td>
<td>&lt;0.0010</td>
<td>82%</td>
<td>⊕⊕⊕⊕</td>
</tr>
<tr>
<td>Rest pain at 12 hours (cm)</td>
<td>9</td>
<td>1.62 (1.61)</td>
<td>2.39 (2.00)</td>
<td>−0.85 (-1.53 to -0.16)</td>
<td>0.02 (P=0.010)</td>
<td>&lt;0.00001</td>
<td>89%</td>
<td>⊕⊕⊕⊕</td>
</tr>
<tr>
<td>Rest pain at 24 hours (cm)</td>
<td>11</td>
<td>1.42 (1.43)</td>
<td>2.11 (1.75)</td>
<td>−0.72 (-1.15 to -0.28)</td>
<td>0.0011 (P=0.006)</td>
<td>&lt;0.0010</td>
<td>88%</td>
<td>⊕⊕⊕⊕</td>
</tr>
<tr>
<td>Rest pain at 36 hours (cm)*</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Rest pain at 48 hours (cm)</td>
<td>2</td>
<td>2.88 (1.51)</td>
<td>3.94 (1.33)</td>
<td>−1.40 (-2.97 to 0.17)</td>
<td>0.08 (P=0.012)</td>
<td>&lt;0.00001</td>
<td>95%</td>
<td>⊕⊕⊕⊕</td>
</tr>
<tr>
<td>Oral morphine consumption at 2 hours (PACU) (mg)</td>
<td>4</td>
<td>2.82 (2.76)</td>
<td>4.51 (4.13)</td>
<td>−1.54 (-3.53 to 0.45)</td>
<td>0.13 (P=0.025)</td>
<td>&lt;0.00001</td>
<td>86%</td>
<td>⊕⊕⊕⊕</td>
</tr>
<tr>
<td>Oral morphine consumption at 24 to 48 hours (mg)*</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Time to analgesic request (hours)</td>
<td>2</td>
<td>23.80 (35.23)</td>
<td>2.76 (5.44)</td>
<td>21.04 (-20.72 to 63.10)</td>
<td>0.32 (P=0.505)</td>
<td>&lt;0.00001</td>
<td>96%</td>
<td>⊕⊕⊕⊕</td>
</tr>
<tr>
<td>Opioid related side effects</td>
<td>11</td>
<td>44/314</td>
<td>84/313</td>
<td>0.43 (0.28 to 0.66)</td>
<td>0.0002 (P=0.007)</td>
<td>0.73</td>
<td>0%</td>
<td>⊕⊕⊕⊕</td>
</tr>
<tr>
<td>Block-related complications</td>
<td>8</td>
<td>0/213</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Patient satisfaction</td>
<td>3</td>
<td>6.75 (1.27)</td>
<td>5.10 (1.29)</td>
<td>1.65 (-0.40 to 2.71)</td>
<td>0.15 (P=0.016)</td>
<td>&lt;0.00001</td>
<td>96%</td>
<td>⊕⊕⊕⊕</td>
</tr>
<tr>
<td>Hospital discharge*</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Persistent postsurgical pain*</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Opioid dependence*</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Health-related quality of life*</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>

*Outcome reported by less than three studies or was not measured.

The quality of evidence was designated as high (⊕⊕⊕⊕), moderate (⊕⊕⊕), low (⊕⊕), very low (⊕), and (N/A) not applicable.

Additional sensitivity analysis was pre-planned to examine the effect of excluding studies (1 published in non-indexed journals; (2) available as abstracts only; or (3) with high risk of bias in one or more domains of the Cochrane risk of bias tool.

Assessment of publication bias
The risk of publication bias in our primary outcomes was assessed using the Egger’s regression test for all outcomes examined.

Data management
Meta-regression was performed using Comprehensive Meta-Analysis 3.0 (Engelwood, USA). Review Manager Software (RevMan V.5.2; Nordic Cochrane Centre, Cochrane Collaboration) was used to create forest and funnel plots.

RESULTS
Our literature search identified 64 unique citations; and additional hand searching of bibliographies and abstracts from conference proceedings identified one potentially eligible citation. From resultant 65 citations, 42 were excluded based on title and abstract alone, due to irrelevant intervention (n=2), irrelevant comparator (n=3), incorrect patient population (n=4), or for not being an RCT (n=33). The remaining 23 potentially eligible citations had their full text reviewed. Of these, 14 were excluded because of irrelevant comparator (n=12)48–50 leaving nine trials. Additional screening of trial registries identified three eligible trials. Consequently, a total of 12 RCTs4 10 37 48–56 were included in this systematic review and meta-analysis. The authors of four4 37 48–50 trials provided additional details that facilitated this review. One study had data extracted from graphs presented in the manuscript.53 A flow diagram of study inclusion is presented in online supplemental appendix B.

Study characteristics
The characteristics and outcomes of interest of the included studies presented in table 1. All 12 randomized trials4 10 37 48–56 included adult females undergoing breast cancer surgery with or without axillary interventions under general anesthesia. These trials included 699 patients, of which 348 of which received ESPB and 351 received parenteral opioids alone (Control). All 12 studies4 10 37 48–56 reported pain scores, and 10 studies4 10 37 49–54 reported postoperative analgesic consumption, the designated co-primary outcomes.

The ESPB technique and analgesic regimens used are presented in table 2. The time of administering ESPB was pre-induction of anesthesia in 11 studies4 10 37 49–56 and post-induction in one study.48 All 124 10 37 48–56 studies used ultrasound localization to deposit local anesthetic below erector spinae muscle in 11 trials4 10 48–56 and one17 did not specify the location. All blocks4 10 37 48–56 were performed between the T2 to T5 levels using bupivacaine (0.25% to 0.5%) in six studies4 48 51 52 54 56 and ropivacaine (0.2% to 0.5%) in six studies.10 37 49 50 53 55 Nerve block adjutants were not co-administered by any included study. The total volume of local anesthetic solution used for ESPB ranged from 16 mL to 40 mL.4 10 37 48–56 The risk of bias assessment for the included studies is presented in online supplemental appendix C.

Primary outcomes
Cumulative 24-hour oral morphine equivalent consumption
Data for this outcome were pooled from 649 patients (ESPB: 323 and Control: 326).4 10 37 48–54 Compared with parenteral

Exploring heterogeneity
For all outcomes in this review, an I² statistic was calculated to evaluate heterogeneity, and values >50% were considered indicative of significant heterogeneity in the pooled estimate.21 When this threshold was met for a primary outcome, meta-regression analysis using mixed effects modeling was performed to explore the interaction between a priori specified clinical predictors and the treatment effect. A coefficient of determination (R²) was also calculated to help quantify the degree to which a covariate explained the variation in treatment effect. Meta-regression analysis was only performed if at least four studies were included in an estimate of effect, and at least two trials within a covariate subgroup. The predetermined covariates and potential sources of heterogeneity included: (i) invasiveness of surgery (partial mastectomy vs mastectomy vs mastectomy with sentinel node biopsy vs mastectomy with axillary dissection); (ii) block localization technique (ultrasound vs ultrasound and nerve stimulator vs anatomic);30 (iii) location of local anesthetic injection (superior to erector spinae muscle vs deep to the erector spinae muscle); (iv) type of local anesthetic used (short-acting (lidocaine and mepivacaine) vs intermediate/long-acting (bupivacaine, levobupivacaine, and ropivacaine));31 (v) dose of local anesthetic used (converted to mg of bupivacaine); (vi) volume of local anesthetic used (15 to 20 mL vs 20 to 30 mL vs 30 to 40 mL); (vii) postoperative analgesic modality (multimodal, inclusive of opioid and other adjutants vs opioid-only);17 33 and (viii) the addition of adjutants that may prolong block duration (eg, epinephrine, dexamethasone, or dexmedetomidine).34 35

In situations where meta-regression analysis could not be performed (ie, <2 trials available for a specific covariate), we resorted to sensitivity analysis with sequential exclusion.

Interpretation
Both co-primary outcomes were interpreted in light of the minimal clinically important difference. For 24-hour morphine consumption, the treatment effect was interpreted in light of a minimum clinically important difference of 30 mg of oral morphine (or 10 mg intravenous morphine). For 24-hour AUC of rest pain, we first pooled rest pain scores at each of the designated time points (PACU, and at 6, 12, and 24 hours) for each arm of the comparisons. The pooled scores were then used to estimate the AUC (expressed in centimeters (cm).hour (h)) and a mean difference of the AUC was calculated. This difference was interpreted in light of a clinically important difference26 27 equivalent to 1.1 cm for acute pain assessment at a single time point,26 which extrapolates to 3.3 cm.h for the full 24-hour interval, based on four measurements (0, 6, 12, and 24 hours) or three subintervals of 0 to 6 hours, 6 to 12 hours, and 12 to 24 hours.

Trial sequential analysis
To confirm adequacy of sample size and reliability of conclusions, we conduct a trial sequential analysis on the co-primary outcomes. A type I error of 5%, a power of 80%, and two-sided testing was used for this analysis. We calculated the required information size based on the calculated WMD for ESPB versus parenteral opioids for each primary outcome. This calculation incorporated a correction for heterogeneity based on the original pooled estimate. The O’Brien-Fleming α-spending function was used to create boundaries for concluding superiority, inferiority, or futility.28 29

Review
(P, corrected threshold of statistical significance) to account for the several secondary outcomes analyzed.23
opioids, ESPB reduced cumulative 24-hour oral morphine equivalent consumption by −17.60 mg (−24.27 to −10.93) (p<0.00001, I²=97%); but the magnitude of this difference remained short of the clinically important threshold (30 mg oral morphine) (figure 1). This result was characterized by high heterogeneity; meta-regression analysis was performed to explore the sources of heterogeneity did not detect an association between morphine consumption and (1) invasiveness of surgery (R²=0.15, p=0.26); (2) local anesthetic dose (R²=0, p=0.90); (3) local anesthetic volume (R²=0, p=0.80); and (4) postoperative analgesic modality (R²=0, p=0.55). Meta-regression could not be performed for the remaining covariates because all studies used ultrasound localization to inject long-acting local anesthetics solution devoid of adjuvants. Our results were robust to sensitivity analysis for location of local anesthetic deposition. The treatment effect was also robust to sensitivity analysis when trials that were published as abstracts, identified from trial registries, or had a high risk of bias in one or more Cochrane domains were excluded from analysis. The risk of publication bias was low for this comparison (p=0.27), and quality of evidence was downgraded to moderate due to heterogeneity.

Trial sequential analysis for cumulative 24-hour oral morphine equivalent consumption (based on a WMD of 17.60 mg between ESPB and parenteral opioids) revealed adequacy of sample size. The cumulative z-curve surpassed the boundary of superiority of ESPB over parenteral opioids for reducing 24-hour oral morphine equivalent consumption, and also surpassed the optimal information size of 198 patients (online supplemental appendix D).

**Difference in the AUC of rest pain**

Data for this outcome were pooled from 589 patients (ESPB: 293 and Control 296) at each of the PACU, 6-hour, 12-hour, and 24-hour time points, and 495 patients (ESPB: 246 and Control: 249) at the 12-hour time point. Compared with parenteral opioids, ESPB decreased the AUC of the pooled rest pain scores by −2.74 cm.h (−3.09 to −2.39) (p<0.00001) over the 24-hour interval; however; but the magnitude of this difference remained short of the clinically important threshold (3.3 cm.h) (figure 2). The quality of evidence was downgraded to moderate due to heterogeneity in the pooled estimates for the individual time points.

Trial sequential analysis for cumulative difference for AUC rest pain over 24-hour (based on a mean difference of 0.90 cm between ESPB and parenteral opioids) also revealed adequacy of sample size. The cumulative z-curve surpassed the boundary of superiority of ESPB over parenteral opioids for reducing AUC rest pain severity, and also surpassed the optimal information size of 1593 patients (online supplemental file 4).

**Analgesic outcomes**

Rest pain at individual time points

ESPB improved pain control in the PACU, and at 6-hour, 12-hour, and 24-hour time points by mean differences of −1.17 cm (−1.68 to −0.66) (p<0.00001, I²=83%), −1.17 cm (−1.67 to −0.66) (p<0.00001, I²=82%), −0.85 cm (−1.53 to −0.16) (p=0.02, I²=89%), and −0.72 cm (−1.15 to −0.28) (p=0.001, I²=87%), respectively (figure 3, table 3). The difference in PACU and 6 hours surpassed the clinically important threshold (1.1 cm); but this was not the case for 12 hours and 24 hours, and no further benefits were observed beyond 24 hours. Furthermore, the difference observed at 12 hours was rendered non-significant when the Bonferroni-Holm correction was applied (p>Pc = 0.01). Evidence quality was downgraded to moderate at PACU, 6, 12, and 24 hours due to heterogeneity, and low at 48 hours due to heterogeneity and imprecision.

**Analgesic consumption in PACU (2 hours)**

Four studies evaluated analgesic consumption in PACU. Compared with parenteral opioids, adding ESPB did not improve opioid consumption in the PACU (table 3). Evidence quality of was downgraded to moderate due to heterogeneity.

**Cumulative 24 to 48 hours morphine consumption**

None of the studies reviewed evaluated this outcome.

**Time-to-first analgesic request**

Two studies evaluated time-to-first analgesic request. Compared with parenteral opioids, adding ESPB did not prolong time-to-first analgesic request. (table 3). Evidence quality was downgraded to low due to heterogeneity and imprecision.

**Patient satisfaction**

Three studies evaluated patient satisfaction. Compared with parenteral opioids, ESPB did not improve patient satisfaction (table 3). Evidence quality was downgraded to moderate due to heterogeneity.

**Time-to-hospital discharge**

None of the studies reviewed evaluated this outcome.

**Opioid-related side effects**

Eleven studies reported opioid-related side effects. Compared with parenteral opioids, ESPB reduced the OR (95% CI) of developing nausea and vomiting by 0.43 (0.28 to 0.66) (p=0.0002, I²=0%) (table 3). Evidence quality was high for this outcome.

**Block-related complications**

Eight studies evaluated block-related complications. None of the patients in this comparison experienced any complications (table 3).

**Long-term outcomes**

None of the studies reviewed evaluated health-related quality of life, persistent postsurgical pain and opioid dependence.

**DISCUSSION**

Our systematic review and meta-analysis provides novel evidence defining the clinical role of ESPB in pain control following breast cancer surgery. Adding ESPB to parenteral analgesia was found to offer modest short-term benefits, including improvements in 24-hour AUC pain severity and cumulative opioid consumption. When put into clinical context, the statistically significant benefits observed lose their importance. For example, the opioid-sparing effect (reduction of 17.60 mg of oral morphine) is equivalent to 0.73 mg of oral morphine per hour or a total of two 5 mg tablets of oxycodone over 24 hours. The modest benefits have to also be balanced against potential risks and complications of ESPB, which include pneumothorax, local anesthetic toxicity, and nerve injury.
It is notable that despite similarities with some of the results of a recent review, our conclusions regarding the clinical role of ESPB are starkly different. This difference is first due to our interpretation of statistically significant findings in the context of clinically important differences. As such, the modest improvements in pain scores (0.72 to 1.17 cm on a VAS scale) observed with ESPB block at the time points assessed fell short of the preset clinical threshold for the 24-hour period, and even short of thresholds of smaller magnitudes that have been reported in pain literature (eg, based on an minimal clinically important difference of 1.3 cm).51–62 The different interpretation can also be attributed to focusing our estimate of ESPB treatment effect on evidence from comparisons with parenteral analgesia, instead of multiple comparisons with active comparators (ie, other truncal blocks), which are best left to a network meta-analysis. Unless ethically compelled, evaluating the efficacy of new interventions should be conducted via comparisons to placebo to improve accuracy and reduce biases.13 This particularly applies to studies of new nerve blocks, where there are no such ethical concerns, as long as alternative analgesic strategies (eg, parenteral analgesia) are made available to study participants.

The expanding list of fascial plane truncal blocks,63–65 promoted for breast and thoracic surgery has largely stemmed from a need for a simpler and safer paravertebral block (PVB) alternative.66–69 ESPB in specific may partially address these challenges, owing to the simplicity of its landmarks, decreased proximity to vital structures, and even potential utility in the anti-coagulated patients.70 71 However, the analgesic profile of ESPB does not seem to bear up for comparisons with parenteral analgesia. Furthermore, the potential safety advantage cannot be confirmed until larger studies are available. In contrast, the pectoralis myofascial plane (PECS) block, among the various PVB alternatives, is now supported by consistent level I evidence.72–74 Not surprisingly, PECS block possesses important prerequisites, including extensive T2 to T5 dermatomal spread;75 76 and blockade of the long thoracic, thoracodorsal, and medial and lateral pectoral nerves, thereby enabling it to provide effective analgesia to the entire breast and axilla.87

It is curious that the magnitude of analgesic benefits observed with ESPB were modest. One plausible explanation relates to the block’s mechanism of action. By deposition of local anesthetic deep to the erector spinae muscle at the level of T5, ESPB has been presented as an intervention capable of blocking thoracic spinal nerves between T1 and L3 levels.1 2 However, several controversies mark the proposed ESPB mechanisms of action and extent of anatomical spread. Cadaveric studies examining ESPB have been conflicting, with several suggested very limited spread to the paravertebral space and sympathetic thoracic chain,78–80 while few have reported some degree of penetration.81 82 Similarly, recent in vivo MRI studies have also suggested that cephalocaudal spread to the paravertebral space and sympathetic chain is highly variable.79 These contrasting results signal that inconsistency of spread and variability of dermatomal coverage may be an intrinsic characteristic of ESPB, owing to the nature of the fascial planes between the spinalis, longissimus thoracis, and iliocostalis muscles that comprise the erector spinae muscles. As with other fascial blocks, spread is expectedly volume dependent;83 but even when accounting for that, spread remains inconsistent, blockade of the dorsal rami seems to be the only common denominator.84 Such inconsistency and variability are in a tradeoff with efficacy and reliability; and may explain why case reports and small case series85 have been successful in reporting ESPB benefits, while clinical trials were not.83 Indeed, a recent investigation of the role of ESPB for rib fractures notably found no benefit when compared sham block.85

There are several strengths of our meta-analysis. The comprehensive literature search included non-English trials as well as additional data provided by authors of relevant trials. The pooled sample size allowed drawing statistical inferences, and the results were interpreted in the context of clinically important differences, allowing a meaningful estimate of the efficacy of ESPB. The majority of patients in this review had modified radical mastectomy, a procedure known for its significant postoperative pain levels,26 and the use of an AUC analysis allowed accounting for time-based variations in analgesic efficacy in this population. Finally, the adjusted threshold of statistical significance served to increase accuracy and reduce the risk of type I error.

Our review also has notable limitations. Being a review of several smaller trials (<50 patients per study), there is always a concern when attempting to produce an accurate estimate of the treatment effect. In addition, lack of data prevented examining several important outcomes, including health-related quality of life, persistent postsurgical pain, pain-related disability, and opioid dependence. Despite the success in resolving some of the heterogeneity by meta-regression and sensitivity analysis, some residual heterogeneity remained unexplained by the prespecified covariates. Finally, though ESPB complications were not detected in this review, the sample size included remains too small to examine this rare outcome.

CONCLUSIONS

Our systematic review and meta-analysis of ESPB 24-hour postoperative pain control and opioid-sparing effects following breast cancer surgery yielded moderate quality evidence of statistically significant but clinically unimportant benefits when the block is added to parenteral analgesia. Current evidence does not support routine use of ESPB. Given the very modest short-term benefits and the risk complications, the block should be considered on a case-by-case basis.

Correction notice This article has been corrected since it published Online First. Negative signs have been added to values throughout the article and reference 26 has been corrected.

Twitter Nasir Hussain @narsi418, Colin JL McCartney @colinjmccartney and Faraj W Abdallah @Faraj_RegAnesth

Contributors All authors contributed meaningfully to the manuscript.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request. All data relevant to the study are included in the article or uploaded as supplementary information.

ORCID iDs Nasir Hussain http://orcid.org/0000-0003-0353-1002 Richard Brull http://orcid.org/0000-0002-7708-8843 Faraj W Abdallah http://orcid.org/0000-0003-2435-6186

REFERENCES


Review


